BTIG keeps Buy rating on Jade Biosciences with $77 price target
BTIG reiterated its Buy rating on Jade Biosciences and a $77 price target after Phase 1 data for JADE101, according to TradingView citing Benzinga.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
BTIG analysts reiterated their Buy rating on Jade Biosciences shares with a $77 price target, TradingView reports. The target implies a 431.0% upside from the October 26 close of $14.50.
The analyst note says Phase 1 results for JADE101 showed an reduction of about 70% in IgA levels. The company is moving quickly: the Phase 3 EVERGREEN trial is expected to start in the fourth quarter of 2026, with interim Phase 2 data due in the second quarter of 2027.
why it matters
A single broker reiterating its rating rarely moves the broader market, but for Jade Biosciences such notes can shape investor sentiment ahead of key trial milestones. The main markers to watch are the Phase 3 start and the interim Phase 2 readout.
tags
instruments
sources
- BTIG reiterates Buy rating on Jade Biosciences, $77 price target — TradingView, 27 October 2026 at 09:45 UTC
- BTIG reiterates Buy rating on Faeth Therapeutics, $55 price target — TradingView, 27 October 2026 at 09:47 UTC
- BTIG reiterates Buy rating on Jade Biosciences, $77 price target — TradingView, 27 October 2026 at 09:47 UTC
- BTIG reiterates Buy rating on Climb Bio, $32 price target — TradingView, 27 October 2026 at 09:52 UTC
- BTIG reiterates Buy rating on Steven Madden, $55 price target — TradingView, 27 October 2026 at 10:18 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗